Twenty allogeneic bone marrow transplant patients were treated with an additional dose of donor cells (boost dose) for graft failure (n = 7), partial graft failure (n = 11) or extensive hemolysis caused by remaining recipient cells producing anti-erythrocyte antibodies (n = 2). Donors were in 12 cases HLA-identical siblings, three mismatched related donors and five unrelated donors. Cell source was in 13 cases bone marrow and in seven peripheral blood progenitor cells. Median time from BMT to booster dose was 3.4 months (range 0.7-59.3). Median infused cell dose was 2.4 × 10 8 /kg patient (range 0.5-19.0). As GVHD prophylaxis most patients were already receiving different combinations of cyclosporine, prednisolone and methotrexate. No preparative treatment was given prior to boost in 16 patients; four received ATG. After boost, 11 patients developed acute GVHD, six grade I, four grade II and one grade III. Except for one patient, acute GVHD after boost was less, or the same grade as after BMT. Six patients developed chronic GVHD, three limited and three extensive. Five patients died within 30 days of the boost. Nine of 15 (60%) evaluable patients became transfusion independent within 30 days and three more within 60 days. Causes of death were: infections six (IP four, pneumonia two), relapse three; and GVHD three. Three out of five patients transplanted with unrelated marrow suffered from severe immunological reactions and died 2-3 months after the boost dose. Patient survival 1 and 3 years after boost was 55% and 43%, respectively. Among patients with hematological malignancies, leukemia-free survival at 3 years was 41%.
cell-depleted graft. 5, 6 In a number of patients continued poor graft function occurs in the absence of graft rejection and continued marrow aplasia places the patient at risk for hemorrhagic and infectious complications. 7 In this study, we retrospectively evaluated the effect and outcome of reinfusion of donor cells (boost) without additional preparative chemotherapy or irradiation in 20 patients.
Patients and methods

Patients
Between December 1981 and July 1996, 20 of 518 patients (4%) undergoing allogeneic bone marrow transplantation at Huddinge Hospital received a second infusion of cells from the original donor without additional preparative chemotherapy or irradiation. Boost cells were given due to failure to show stable engraftment of platelets and/or leukocytes, or extensive hemolysis caused by remaining donor cells producing anti-erythrocyte antibodies. Among patients transplanted with a unrelated donor, three were mismatched in one HLA-DP locus and one in the DP and DQ loci.
In 15 of these 20 patients potential risk factors for poor graft function were identified: three received T celldepleted marrow, four received low marrow cell dose (Ͻ2.0 × 10 8 /kg), three had a non-HLA-identical donor and five had an unrelated donor.
Patient characteristics are summarised in Table 1 .
Engraftment
Marrow engraftment was monitored by daily blood counts, and when appropriate, marrow aspirate cellularity. Engraftment was defined as the first of 2 consecutive days when the PMN was у0.5 × 10 9 /l. Primary graft failure was defined as marrow hypoplasia (Ͻ10% cellularity in marrow) with a peripheral PMN less than 0.5 × 10 9 /l persisting beyond day 21 post-BMT, and secondary graft failure as marrow hypoplasia with a requirement for frequent (уonce weekly) platelet transfusions beyond day 60.
Initial transplant
For 11 of the patients with haematological malignancies conditioning therapy for the initial transplant was cyclophosphamide (60 mg/kg) for 2 consecutive days followed by TBI as a single 10 Gy dose with the lungs shielded to receive no more than 9 Gy. 8 Three patients receiving T celldepleted marrow were given 3 days of 2 Gy TLI followed by 2 days of Cy (60 mg/kg) and 7.5 Gy TBI given at a rate of 26 cGy/min with the lungs shielded to receive no more than 7 Gy. 9 The three remaining patients with hematological malignancies received Bu 4 mg/kg for 4 days followed by 2 days of 60 mg/kg/day Cy (n = 1), alkeran 4 mg/kg and TBI 10 Gy (n = 1) and 12 Gy fractionated TBI (4 × 3 Gy) with 2 days of 60 mg/kg Cy and 30 mg/kg VP-16 (n = 1). The two patients with SAA were given 4 days of Cy 50 mg/kg. The patient with San Filippo received 4 days Bu 80 mg/m 2 followed by 4 days Cy 2 g/m 2 . The two patients with severe aplastic anemia and five with unrelated donors were given 5 days of ATG (3-5 mg/kg) in addition to conditioning therapy. One patient with SAA was transplanted twice from the same donor. Before the second transplant he received 3 × 2 Gy TLI, Cy and 10 Gy TBI. Details have been described previously.
10,11
The initial median marrow cell dose was 2.5 × 10 8 /kg, range 0.1-14.0 × 10 8 /kg, calculated as total number of NC in the graft minus total WBC from the same volume of donor peripheral blood. GVHD prophylaxis was MTX combined with CsA in 10 cases, T cell depletion in three, monotherapy with either MTX or CsA in six and no prophylaxis in one patient (twin). Details have been published previously. 9, 12 Six patients never showed any signs of engraftment, and were transfusion-dependent until boost cell infusion. These patients were considered as primary graft failures. Fourteen of 20 (70%) patients engrafted, but later showed signs of poor graft function (secondary graft failure, n = 12) or extensive hemolysis caused by anti-erythrocyte antibodies produced by remaining recipient cells (n = 2). Median days to PMN Ͼ0.5 × 10 9 /l were 19 (11-45) (n = 14). Thirteen (65%) patients developed acute GVHD, five grade I, four grade II and four grade III.
Boost
Boost cells were given due to failure to show stable engraftment of platelets (n = 11), platelets and leukocytes (n = 7) or extensive hemolysis (n = 2) caused by remaining recipient cells producing anti-erythrocyte antibodies. The donor cells were obtained from bone marrow (n = 13) or peripheral blood (n = 7). Unstimulated peripheral blood cells were used in four cases and in three cases the donor was stimulated with G-CSF (10 g/kg/day for 4 days) prior to leukapheresis. Four patients with unrelated donors received peripheral blood cells (three unstimulated) and one bone marrow. Median infused booster cell dose was 2.4 × 10 8 /kg (range 0.5-19.0). No preparative treatment was given prior to boost in 16 patients. Four patients received 2-5 days of ATG (3-5 mg/kg/day). GVHD prophylaxis immediately before and after boost cells was CsA in four cases; CsA + MTX, two; CsA + prednisolone, six; MTX + prednisolone, four; CsA + MTX + prednisolone, three; and no prophylaxis in one case. Median time from initial transplant to booster was 3.4 months, range 0.7-59.3 months (Figure 1 ).
Virus infections
Samples for detection of CMV were taken weekly during the first 3 months after BMT. CMV was detected by either standard technique (before 1988), rapid isolation technique (1988) (1989) (1990) (1991) or, from January 1992, by a nested PCR technique. 13 Pre-emptive anti-viral therapy with ganciclovir (5 mg/kg twice daily) or foscarnet (60 mg/kg twice daily) was initiated for 2 weeks after a positive rapid culture or, from 1992, two consecutive positive PCR tests. 14 
Statistical methods
The Kaplan-Meier product limit method was used to determine estimates of engraftment, survival and GVHD following boost cell infusion. In comparing cell counts before and after cell infusion, the Mann-Whitney U test was used. Cal- culations were with Statistica/W (Statsoft, Tulsa, OK, USA). All measurements of variation are expressed as mean ± s.e.
Results
Hematological recovery
Hematological recovery in 15 evaluable patients is shown in Figure 2a -c. Fifteen patients (75%) showed improvement of graft function as measured by PMN Ͼ0.5 × 10 9 /l or became independent of platelet transfusions (Figure 3 ). Platelet counts as well as PMN and hemoglobin values were significantly increased at 1 month after boost.
Viral infections
Before boost, 10/20 (50%) patients were positive for CMV by either isolation or PCR. There were no significant differences in cell counts before and after treatment for CMV viremia. In patients without graft failure (n = 498), 259 (52%) were positive for CMV. Three patients (15%) with graft failure were positive for hepatitis B or C virus, while 26 of the patients without graft failure (5%) had hepatitis (P = 0.2).
Primary graft failure
Three out of six patients with primary graft failure died early without engraftment. Three patients achieved PMN Ͼ0.5 × 10 9 /l at 2, 20 and 33 days after boost. Two of these three patients are still alive with good graft function +13 and +125 months after boost. The third patient relapsed 8 months after boost and died 7 months later. Hematological recovery is shown in Figure 2a -c.
Secondary graft failure
Two of 12 patients with secondary graft failure died 6 and 13 days after boost, still platelet transfusion-dependent, one in relapse and one with acute GVHD and septicemia. Ten patients became platelet transfusion-independent on a median of day 15, range 1-270, after boost ( Figure 4 ). The patient who was transfusion dependent until day 270 had ITP transferred from the donor. The spleen was removed 9 months after boost and thereafter platelet counts returned to normal values. Six patients are alive with good graft function 18-162 months after boost. Hematological recovery is shown in Figure 2a -c.
Patients with hemolysis
Two patients with extensive hemolysis before boost, temporarily improved. Both patients had an unrelated donor and received non-stimulated peripheral stem cells as boost (cell dose: 3.2 and 1.2 × 10 8 /kg, respectively). Blood groups of the patients were O and B, while both donors were blood group A. Before BMT antibody titers against blood group A antigen were 1:32 in both patients. Case 1: A 25-yearold female with CML. Two months after boost she developed an aspergillus infection. This made the hemolysis worse and she subsequently died with hemolysis and aspergillus pneumonia 3 months after boost. Case 2: A 24-year-old male with CML who developed acute GVHD grade III and died in liver failure 2 months after boost.
GVHD
After boost cells, 11 of 20 (55%) patients developed acute GVHD, six grade I, four grade II and one grade III. Probability of grades II-IV acute GVHD were 31%. Three of these patients died with GVHD, two in combination with infections. Eight patients had grade II-III of acute GVHD before boost. After boost, six of these had a lower grade. One had grade II before and after boost. Another patient experienced grade II before and grade III after boost (Table 2) . Six patients developed chronic GVHD, three mild and three severe. Probability of developing chronic GVHD was 50%. One patient died with chronic GVHD.
Causes of death
Among patients with primary graft failure, three died within 20 days after boost cell infusion. Causes of death were relapse (n = 1) and aspergillus pneumonia (n = 2). An additional patient relapsed 8 months after boost, and died 7 months later. Among those with secondary graft failure two patients died within 1 week of boost cells, one with relapse and one with interstitial pneumonia (IP) in association with acute GVHD. Four later deaths occurred in this group. Pneumonia in two cases, IP in one and chronic GVHD in one. Both patients with hemolysis died 2-3 months after boost from aspergillus IP and acute GVHD, respectively.
Overall survival
Among 12 patients receiving boost cells from HLA-identical siblings, six (50%) are alive and well. Two out of five recipients of unrelated boost cells are alive and well.
Among those with unrelated donors who received peripheral cells (n = 4), three suffered from severe immunological reactions, including acute GVHD and hemolysis and died 2-3 months after boost.
Among the whole group, patient survival at 1 year was 55% and at 3 years 43% (Figure 4) . Eight patients are still alive with good graft function with a median follow-up time of 6.3 years (range 1.1-13.9).
Discussion
In this study, we evaluated our results in bone marrow transplant patients receiving a boost dose of donor cells without conditioning for graft failure. The reasons for graft failure in these patients were not clearly known. In 15 patients potential risk factors were identified such as low marrow cell dose, T cell-depleted graft, HLA-mismatched donor or unrelated donor. [2] [3] [4] [5] [6] Ten of the patients had a CMV infection prior to boost. These virus infections may have been responsible for the pancytopenia or delayed platelet recovery in these patients as described by Verdonck et al. 15 However, antiviral treatment had no impact on the pancytopenia. Hepatitis B or C virus infections can also cause marrow aplasia. Four patients in this study suffered from HCV or HBV infections. Two patients relapsed shortly after boost. The graft failure in these patients was possibly due to relapse not apparent at the time of the boost. First and co-workers 16 found a correlation between prolonged thrombocytopenia and severe GVHD or trimetoprim-sulfametoxazol treatment. In our study, eight patients (40%) had aGVHD уII before boost. This is a somewhat higher frequency than in patients not boosted, being 11% for HLAidentical siblings and 15% for recipients of unrelated marrow. 17 The mechanism for the thrombocytopenia may be either peripheral destruction associated with GVHD or decreased production. To give donor cells after BMT induces a risk of severe GVHD or aplasia. 18 In this study we had no cases with prolonged aplasia, except for one patient who was platelet transfusion dependent 9 months after boost. This was due to ITP transferred from the donor, and was cured by splenectomy. Bolger et al 19 reported a high rate of acute GVHD grades II-IV (71%) after reinfusion of donor cells. In our study, five patients (31%) developed grade II-IV acute GVHD. Except for one patient, acute GVHD was no more severe after boost as compared to after BMT. Chronic GVHD occurred in six of the 12 patients surviving Ͼ150 days (50%). Moderate to severe acute GVHD was seen in only five cases and severe chronic GVHD in three. This is no more than might be expected after initial BMT and in line with what Davies et al 20 reported but less than reported by other groups. 19, [21] [22] This was probably because most patients in our study received GVHD prophylaxis after boost, and three in addition received ATG before boost. Three of four patients receiving peripheral cells as a boost from an unrelated donor suffered from severe immunological reactions. We have previously treated a few patients with peripheral blood progenitor cells without any adverse immunological reactions including moderate to severe GVHD. 23 Early allo-BMT immunosuppression con- Hem MUD Cy/TBI/AGG M+C I 0 C +P 0 0 Died d92 Asp pneum S = secondary graft failure; P = primary graft failure; Hem = hemolysis; MM = mismatch; MUD = matched unrelated donor; Mel = melphalan; M = methotrexate; C = cyclosporine; TcD = T cell depletion.
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sisted of ATG or OKT-3 and high-dose cyclosporine combined with methotrexate. 17 However, by giving a boost which contains a high number of T cells after BMT the risk for GVHD or other immunological adverse events may be increased. Therefore, the immunosuppression for those patients probably has to be more intense. Even though these donors were matched for HLA-A, -B and -DR, DP, DQ or other minor MHC molecules might trigger the immune response in these cases.
Hematopoetic recovery after reinfusion of donor cells was successful in the majority of patients. Three of six patients who received boosts for primary graft failure engrafted, while 10 of 12 with secondary graft failure experienced improved graft function (Figure 2 ). The five patients who did not engraft died early. The overall survival was 55% at 1 year and 43% at 3, which is slightly better than reported by other groups. 19, 20 In agreement with the two previous reports infections were the main cause of death in our material. 19, 20 This report show that reinfusion of donor cells is frequently successful in achieving engraftment after graft failure. Furthermore, encouraging long-term survival was seen.
